Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Mouse (Murine) BTG2 Antibodies:
anti-Human BTG2 Antibodies:
anti-Rat (Rattus) BTG2 Antibodies:
Go to our pre-filtered search.
Human Polyclonal BTG2 Primary Antibody for IHC (p), WB - ABIN654080
Zhang, Huang, Wu, Wang, Wu: Impact of BTG2 expression on proliferation and invasion of gastric cancer cells in vitro. in Molecular biology reports 2010
Show all 2 Pubmed References
Dog (Canine) Polyclonal BTG2 Primary Antibody for WB - ABIN2778006
Tsui, Hsieh, Lin, Chang, Juang: Triiodothyronine modulates cell proliferation of human prostatic carcinoma cells by downregulation of the B-cell translocation gene 2. in The Prostate 2008
Cow (Bovine) Polyclonal BTG2 Primary Antibody for WB - ABIN2778007
Park, Kim, Baek, Park, Lim, Seo, Chun: B-cell translocation gene 2: expression in the rat ovary and potential association with adenine nucleotide translocase 2 in mitochondria. in Molecular and cellular endocrinology 2013
Peroxisome proliferator-activated receptor alpha (PPARalpha (show PPARA Antibodies)) target gene expression was almost absent in contrast to increased lipid synthesis in the TIS21 protein (TIS21) knockout (TIS21-KO) mice compared to WT mice.
Tumor suppressors BTG1 (show BTG1 Antibodies) and BTG2 regulate early mouse B-cell development.
Results identify a key molecular mechanism by which the BTG2-PRMT1 (show PRMT1 Antibodies) module regulates pre-B cell differentiation and inhibits pre-B cell leukemogenesis.
Results suggest that Btg2 is an anti-adipogenic factor and its expression is controlled by the Stat3 (show STAT3 Antibodies) signaling pathway.
these data show that both Btg1 (show BTG1 Antibodies) and Btg2 are required for normal vertebral patterning of the axial skeleton, but each gene contributes differently in specifying the identity along the anterior-posterior axis of the skeleton.
Btg2 overexpression in vivo and in vitro induced all the observed changes during interdigit regression, including oxidative stress, arrest of cell cycle progression, transcriptional regulation of senescence markers, and caspase (show CASP3 Antibodies)-mediated apoptosis.
study provides a novel molecular mechanism of BTG2-mediated induction of hepcidin (show HAMP Antibodies) gene expression, thereby contributing to a better understanding of the hepatic hepcidin (show HAMP Antibodies) production involved in iron homeostasis
TIS21 is required for development of spiral ganglion cells
we show that the putative tumor suppressor gene Btg2 is consistently downregulated in high grade gliomas and that its downregulation is necessary for a cell to maintain the malignant phenotype.
Mice lacking the Tis21 3' UTR (show UTS2R Antibodies) develop a microcephalic neocortex with fewer neurons.
Open data and immunohistochemical analysis were performed to confirm the role of TIS21(/BTG2) expression in various human breast cancer tissues. It was observed that TIS21(/BTG2) inhibited mTORc1 activity by reducing Raptor (show RPTOR Antibodies)-mTOR (show FRAP1 Antibodies) interaction along with upregulation of tsc1 (show TSC1 Antibodies) expression.
we found that miR (show MLXIP Antibodies)-27-3p was overexpressed in gastric cancer tissues and cell lines and that BTG2 was a direct and functional target of miR (show MLXIP Antibodies)-27a-3p in gastric cancer
Effect of TIS21 on the regulation of p53 (show TP53 Antibodies) activity was confirmed by knockdown of TIS21 expression by RNA interference.
TIS21 attenuated Doxorubicin-induced cancer cell senescence by inhibiting linear actin nucleation via Nox4 (show NOX4 Antibodies)-ROS (show ROS1 Antibodies)-ABI2 (show ABI2 Antibodies)-DRF (show MPO Antibodies) signal cascade
Data indicate that BTG2, MAP3K11 (show MAP3K11 Antibodies), RPS6KA1 (show RPS6KA1 Antibodies) and PRDM1 (show PRDM1 Antibodies) as putative targets of microRNA miR (show MLXIP Antibodies)-125b.
The results indicated that BTG2 expression was downregulated in skin cancer cell lines. Overexpression of BTG2 significantly inhibited cell proliferation, cell cycle progression, and the invasion and migration of skin cancer cells.
Overexpression of BTG2 inhibited the proliferation and migration/invasion of human osteosarcoma cells in vitro
clinical data support conclusions generated from patient-derived xenograft models and indicate that BTG2 expression is a candidate prognostic biomarker for TNBC.
miR (show MLXIP Antibodies)-21 was found to be overexpressed and BTG2 was found to to be downregulated in HepG2 liver cancer cells.
BTG2 stimulates mRNA deadenylation via CAF1 (show CHAF1B Antibodies) activation through interaction with PABPC1 (show PABPC1 Antibodies). Interaction of BTG2 with the first RRM domain of PABPC1 (show PABPC1 Antibodies) is required for BTG2 to control cell proliferation.
The full length sequences of cDNA and genomic DNA of BTG2 gene from the porcine skeletal muscle, was cloned.
The protein encoded by this gene is a member of the BTG/Tob family. This family has structurally related proteins that appear to have antiproliferative properties. This encoded protein is involved in the regulation of the G1/S transition of the cell cycle.
B-cell translocation gene 2, anti-proliferative
, BTG family, member 2
, protein BTG2
, B-cell translocation gene 2
, B cell translocation protein 2
, BTG family member 2
, NGF-inducible protein TIS21
, NGF-inducible anti-proliferative protein PC3
, nerve growth factor-inducible anti-proliferative
, pheochromacytoma cell-3
, B-cell translocation protein 2
, Early induced gene B-cell translocation gene 2
, NGF-inducible anti-proliferative putative secreted protein
, cell surface alloantigen